Acacia Research Corporation — FY2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. This is an annual filing; the supplied text does not provide clear standalone fourth-quarter financial results.
Business context
Acacia is an opportunistic capital platform focused on acquiring undervalued businesses and assets. Its operations comprise patent licensing and enforcement, industrial printing through Printronix (acquired in October 2021), and remaining investments in its Life Sciences Portfolio. The company reported two operating segments: Intellectual Property Operations and Industrial Operations.
Financial performance and liquidity
| Metric | FY2022 | FY2021 |
|---|---|---|
| Revenue | $59.2 million | $88.0 million |
| Operating income (loss) | $(40.1) million | $14.5 million |
| Net income (loss) attributable to Acacia | $(125.1) million | $149.2 million |
| Operating cash flow | $(37.3) million | $13.3 million |
| Investing cash flow | $184.5 million | $35.8 million |
| Financing cash flow | $(166.1) million | $59.7 million |
- Revenue comprised $19.5 million from Intellectual Property Operations, down 74% year over year, and $39.7 million from Industrial Operations. Printronix contributed $27.7 million more revenue than in 2021, which included only its post-acquisition period of roughly three months.
- Consolidated gross profit was $21.8 million, or approximately 36.9% of revenue. Intellectual Property Operations recorded a $3.9 million segment operating loss; Industrial Operations recorded $1.1 million of segment operating income. Parent-company general and administrative expense was $37.3 million.
- Results included a $263.7 million unrealized loss on equity securities, partly offset by $125.3 million of realized gains and $42.5 million of earnings on an equity investment. The unrealized loss primarily reflected reversal of earlier gains on Life Sciences Portfolio securities sold in 2022.
- Cash, cash equivalents, equity securities and long-term restricted cash totaled $349.4 million at year-end, versus $671.1 million a year earlier. Cash and cash equivalents alone were $287.8 million. Current assets were $428.0 million and current liabilities were $87.2 million.
- Senior secured notes had $60.0 million principal outstanding at year-end, with maturity on July 14, 2023; the balance-sheet carrying amount was $60.5 million. The company also reported $84.8 million of Series B warrant liabilities and $19.9 million of Series A redeemable convertible preferred stock.
Material changes versus the prior year
- Revenue fell 33%, principally because patent-licensing revenue declined by $56.5 million; the comparison is affected by Printronix being consolidated for only part of 2021.
- Operating results swung from income to loss, and attributable net income swung from $149.2 million to a $125.1 million loss. The change reflected lower patent revenue, higher operating and corporate expenses, and the large unrealized investment loss, partly offset by realized gains and joint-venture earnings.
- Operating cash flow moved from a $13.3 million inflow to a $37.3 million outflow. Investing cash flow was positive largely because proceeds from sales of equity securities exceeded purchases; financing outflows included $120.0 million of note paydowns and $51.0 million of share repurchases.
- Acacia acquired no new patent portfolios in 2022, compared with one in 2021. It reported 17 new license agreements in 2022 versus 23 in 2021.
Outlook, transactions, risks and unusual items
- Management said cash balances, anticipated operating cash flows and recapitalization-related transactions were expected to cover requirements for at least twelve months from the report date. This assessment depends partly on completing the Starboard recapitalization and related transactions. No quantified earnings or revenue guidance was provided.
- The October 2022 recapitalization is intended to simplify Starboard’s investment structure. A February–March 2023 rights offering raised approximately $79.2 million gross in total, mostly through the concurrent private offering to Starboard. The remaining steps included a planned exercise of 31.5 million Series B warrants, conversion of Series A preferred stock subject to stockholder approval, and a $66 million recapitalization payment at the warrant-exercise closing. The filing described these steps as pending at the time, with a July 2023 deadline.
- The Life Sciences Portfolio was acquired for approximately $282 million in 2020. Acacia reported $504.3 million of cumulative proceeds through 2022 and retained investments valued at $68.4 million at year-end. Fair-value changes can materially affect reported earnings and liquidity measures.
- Management reported that an independent investigation confirmed former CEO Clifford Press provided inaccurate expense information, used company funds for personal expenses, and misrepresented compliance with a Board directive. Acacia filed an arbitration demand seeking restitution and other remedies. The CEO departed in November 2022; the CEO and CFO roles were interim at or shortly after year-end.
- Acacia paid $4.8 million in the fourth quarter of 2022 to resolve a dispute related to the Life Sciences Portfolio. Patent enforcement litigation continues, with potentially significant legal costs, delays, adverse rulings or sanctions. A separate patent-related case had summary-judgment motions pending.
- Key business risks include volatile and concentrated patent-licensing revenue, lack of recent patent-portfolio intake, valuation swings in equity investments, dependence on Starboard for sourcing and expertise, recapitalization execution and dilution, and Printronix’s exposure to supply, customer, foreign-market and declining print-consumption risks.
Important facts for investors to verify
- Whether the Series B warrant exercise, preferred-stock conversion, related stockholder approvals and $66 million payment were completed on the stated terms, and the resulting cash, debt and share count.
- The composition, liquidity and subsequent valuation or sale proceeds of remaining Life Sciences Portfolio investments, especially the Arix and Viamet-related interests.
- Whether patent licensing revenue and new portfolio acquisitions recover, given the 2022 revenue decline and absence of new portfolio acquisitions during the year.
- Printronix’s current operating performance, supply and customer exposure, and its ability to sustain consumables and service revenue.
- Developments in leadership succession and the arbitration against the former CEO, as well as outcomes of material patent and other legal proceedings.